Imugene Ltd · ASX:IMU
Imugene — Shareholder Meeting (July 2018)
10 slides from Imugene's shareholder meeting presentation, Jul 9, 2018
Slide 1: Harnessing B-Cells for Cancer Immunotherapy
For personal use only ASX:IMU v HARNESSING B-CELLS FOR CANCER IMMUNOTHERAPY Leslie Chong Managing Director & Chief Executive Officer July 2018 General Meeting
Slide 2: Notice: Forward Looking Statements
For personal use only NOTICE: FORWARD LOOKING STATEMENTS Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, unce
Slide 3: A Team with Track Record in Drug Development
A TEAM WITH TRACK RECORD IN DRUG DEVELOPMENT For personal use only Leslie Chong (Sydney, Australia) Prof Ursula Wiedermann (Vienna, Austria) Managing Director & Chief Executive Officer Chief Scientific Officer • Over 20 years of oncology experience in Phase I – III of • Co-inventor of HER-Vaxx clini
Slide 4: A Better Way to Make Antibodies to Treat Cancer?
For personal use only A BETTER WAY TO MAKE ANTIBODIES TO TREAT CANCER? In a facility: Using B-cells in your body VS v B-cells are cells in the human body that naturally produce millions of antibodies For example, Merck’s Keytruda Teaching B-cells to make antibodies using peptide antigens 4
Slide 5: Strategic Acquisition
STRATEGIC ACQUISITION For personal use only Ohio State University and Mayo Clinic B-cell peptide vaccine portfolio • Opportunity to create the dominant position globally in B-cell peptide vaccines and therapeutics. • Professor Kaumaya’s work in the area of check-point inhibitors and tumor-associated
Slide 6: OSU / Mayo Clinic Worldwide, Exclusive License
OSU / Mayo Clinic For personal use only WORLDWIDE, EXCLUSIVE LICENSE v Her- Ongoing Six additional Three year Six patent IND ready PD- 2 clinical clinical candidates R&D contract families, 1 clinical trial Her-1, Her-2, Her- with access to trial 3, VEGF, IGF-1R Ohio 22 patents (Phase 1) (Phase 2) CD
Slide 7: Expanded Imugene B-Cell Vaccine Pipeline
EXPANDED IMUGENE B-CELL VACCINE PIPELINE For personal use only Strengthens and broadens Imugene’s B-cell vaccine pipeline CLINIC OR CLINIC READY OSU / MAYO CLINIC IMUGENE PD-1 Her-2 + Her-2 HER-Vaxx PD-1 Clinic Ready Phase 2 PD-1 Combo v Phase 1b/2 Mimotope Candidate Cancer Vaccine Proposed DISCOVER
Slide 8: Why Select and Target PD-1 for B-Cell Vaccination?
For personal use only WHY SELECT AND TARGET PD-1 FOR B-CELL VACCINATION? Monoclonal antibody immunotherapies Whilst acknowledging the rapid rise in Keytruda® (Merck) and clinical trials involving PD-1 and their Opdivo® (BMS) targeting PD-1 sold combination with other treatments*, a PD-1 USD$3.8B and
Slide 9: Acquisition Summary
ACQUISITION SUMMARY For personal use only • Funding: Capital raise to fund expanded clinical programs through key Strengthens and broadens our clinical data readouts and value inflection points B-cell cancer vaccine pipeline • Management team that has delivered on all critical milestones over the la
Slide 10: Leslie Chong contact details
For personal use only Leslie Chong Chief Executive Officer & Managing Director v leslie.chong@imugene.com +61 458 040 433